ARCHIVES

J&J Withdraws Power Morcellators, Citing Risk of Disseminating Cancer

This article is from The Cancer Letter archive.

Vol. 40 No. 31 | August 1, 2014

Download PDF Visit The Full Archive

Related Articles

Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas

December 28, 2012

House Aims to End Budget Markup Early; Natcher Sees Most Difficult Year

June 26, 1992

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

May 21, 2004

Study Links Obesity To Higher Risk of Ovarian Cancer

January 30, 2009

In Brief: Friedell To Head McDowell Network, New Kentucky Cancer Center; Nine Expiring Core Grants Approved

October 29, 1982

FDA Lacks Resources To Deal With Onslaught Of New Cancer Drugs, Friedman Tells Agency

August 14, 1992